Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

External reference pricing goes global

This article was originally published in Scrip

Executive Summary

Do you know how drug prices are set in Guam, Kiribati or Micronesia? Or whether countries like Bhutan, Papua New Guinea and Uzbekistan use external reference pricing (ERP)? If not, you're in good company. The World Health Organization and Health Action International have no idea either, and have asked people living in 39 countries around the world to let them know whether they operate any kind of drug pricing systems, and if so whether these include ERP.

You may also be interested in...



EU Eases GMO Rules To Speed Trials Of COVID-19 Vaccines

The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment. 

EU Issues Post-Brexit Clinical Trial Warning

The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line. 

COVID-19: Gilead To Fill Remdesivir Supply Gap In EU

As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel